Trial · NCT07522151
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator-assessed EFS | About 8 years | Assessments BY INVESTIGATORS |
| Secondary | Complete response (pCR) rate as assessed by the Pathology Review Committee (PRC) | About 3 years | Complete remission (pCR) rates after surgery |
| Secondary | Rate of pathologically significant response (MPR) as assessed by the Pathology Review Committee (PRC) | About 3 years | Pathologically significant response (MPR) rate after surgery |
| Secondary | EFS as assessed by an independent review committee (IRC) | About 8 years | Independent Review Committee (IRC) evaluation |
| Secondary | DFS, as assessed by investigator /IRC | About 8 years | Investigator /IRC assessment |
| Secondary | pCR rate by central pathological evaluation | About 3 years | Central pathological evaluation was studied |
| Secondary | R0 resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| Secondary | D2 radical resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| Secondary | objective response rate (ORR) of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| Secondary | The incidence of adverse events (AE) were evaluated according to NCI-CTCAE 6.0 | About 4 years | NCI-CTCAE 6.0 was used for evaluation |
| Secondary | The severity of serious adverse events (SAE) were evaluated according to NCI-CTCAE 6.0 | About 4 years | NCI-CTCAE 6.0 was used for evaluation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07522151/registered